Metastatic Castration-Resistant Prostate Cancer Market

Market Overview:

The 7 major metastatic castration-resistant prostate cancer markets reached a value of USD 7,275.4 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 12,840.0 Million by 2035, exhibiting a growth rate (CAGR) of 5.3% during 2025-2035.

The metastatic castration-resistant prostate cancer market has been comprehensively analyzed in IMARC's new report titled "Metastatic Castration-Resistant Prostate Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Metastatic castration-resistant prostate cancer (mCRPC) is an advanced stage of cancer in which the tumor has spread to various parts of the body and continues to grow despite hormone therapy. It is particularly an aggressive and challenging form of the disease that can metastasize to the bones, lymph nodes, or several other distant organs. The common symptoms of this ailment include deep aches in the bones, fatigue, increased frequency of urination, erectile dysfunction, unexplained weight loss, changes in appetite, swelling in the legs or lower extremities, constipation, diarrhea, urinary incontinence, etc. The diagnosis of mCRPC typically involves a combination of clinical evaluation, laboratory tests, medical history, and physical examination. A computed tomography (CT) scan, which combines X-rays to create detailed cross-sectional pictures of the body, is also performed to visualize the presence of metastases in the body. Additionally, genetic testing is recommended for the identification of specific genome mutations or alterations that may be contributing to the underlying disease. The healthcare provider will further conduct a tissue biopsy to confirm the diagnosis of the tumor and assess its histological subtype.

The rising cases of hormonal imbalances, which allow cancer to survive and even thrive in low-androgen environments, are primarily driving the metastatic castration-resistant prostate cancer market. In addition to this, the escalating prevalence of genetic mutations that impair the cell's ability to repair DNA damage, leading to the development of aggressive tumors, is also creating a positive outlook for the market. Moreover, the widespread adoption of stereotactic body radiation therapy, since it can deliver precise doses of energy beams to targeted tumor sites, thereby providing localized treatment, is further bolstering the market growth. Apart from this, the inflating application of immune checkpoint inhibitors, like pembrolizumab and nivolumab, to stimulate the defense system's response against cancerous cells and improve the quality of life in patients is acting as another significant growth-inducing factor. Additionally, the emerging popularity of targeted therapies, such as enzalutamide, abiraterone acetate, apalutamide, etc., that can block specific pathways involved in the proliferation and progression of tumor growth is expected to drive the metastatic castration-resistant prostate cancer market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the metastatic castration-resistant prostate cancer market in the United States, EU4 (Germany, Spain, Italy and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for metastatic castration-resistant prostate cancer and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the metastatic castration-resistant prostate cancer market in any manner.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the metastatic castration-resistant prostate cancer market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the metastatic castration-resistant prostate cancer market
• Reimbursement scenario in the market
• In-market and pipeline drugs
   

Competitive Landscape:

This report also provides a detailed analysis of the current metastatic castration-resistant prostate cancer marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the metastatic castration-resistant prostate cancer market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the metastatic castration-resistant prostate cancer market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the metastatic castration-resistant prostate cancer market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2019-2035) of metastatic castration-resistant prostate cancer across the seven major markets?
• What is the number of prevalent cases (2019-2035) of metastatic castration-resistant prostate cancer by age across the seven major markets?
• What is the number of prevalent cases (2019-2035) of metastatic castration-resistant prostate cancer by gender across the seven major markets?
• How many patients are diagnosed (2019-2035) with metastatic castration-resistant prostate cancer across the seven major markets?
• What is the size of the metastatic castration-resistant prostate cancer patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of metastatic castration-resistant prostate cancer?
• What will be the growth rate of patients across the seven major markets?
   

Metastatic Castration-Resistant Prostate Cancer: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for metastatic castration-resistant prostate cancer drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the metastatic castration-resistant prostate cancer market?
• What are the key regulatory events related to the metastatic castration-resistant prostate cancer market?
• What is the structure of clinical trial landscape by status related to the metastatic castration-resistant prostate cancer market?
• What is the structure of clinical trial landscape by phase related to the metastatic castration-resistant prostate cancer market?
• What is the structure of clinical trial landscape by route of administration related to the metastatic castration-resistant prostate cancer market?